Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

The most common grade 3 or 4 adverse reactions related to eribulin (occurring in over 5% of patients) were neutropenia (57%), asthenia or fatigue (10%), and peripheral neuropathy (8%). Febrile ...

Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...